Medical Condition News

RSS

People with rare mutations of gene MUTYH at increased risk of bowel cancer

CANCER RESEARCH UK funded scientists have found that people who carry rare mutations within both copies of a gene called MUTYH are 28 times more likely to develop bowel cancer compared to the general population, according to a study in the Journal of Clinical Oncology.

1 Oct 2009

New software to detect multiple sclerosis before brain damage occurs

Researchers of the Unit for Systems Biology of the University of Jaén, led by Francisco J. Esteban, are developing a software for clinical use to detect multiple sclerosis even before the typical brain damage of this neurodegenerative disease appear. In order to do so, this scientific multidisciplinary team is calculating the fractal dimension of the brain images registered on magnetic resonance imaging.

1 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Catalyst Pharmaceutical Partners, Inc. today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.

1 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

Women create nationwide movement to eradicate breast cancer

More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.

1 Oct 2009

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Women with psoriasis and psoriatic arthritis are markedly more likely than men to suffer from the emotional and psychological effects of the diseases, according to survey data released by the National Psoriasis Foundation today.

1 Oct 2009

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%).

1 Oct 2009

Grand Opportunity grant to pursue "whole-genome" sequencing of patients with autism

Children's Hospital Boston, with the Broad Institute and Harvard Medical School, has been awarded a Grand Opportunity grant from the National Institute of Mental Health as part of the federal stimulus package, to pursue "whole-genome" sequencing of patients with autism, using new technologies for rapid DNA sequencing to better understand autism's causes.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Intoxicated trauma patients have higher survial rates than sober patients: Study

Trauma patients who were intoxicated before their injuries were more likely to survive than trauma patients who suffered similar injuries but were sober at the time, according to a study published in the October edition of the American Surgeon that was conducted by researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

1 Oct 2009

NIH awards $10.5 million grant for OCD treatment research

A new research center exploring the science underlying a potential new treatment for obsessive-compulsive disorder has been established at the University of Rochester Medical Center, thanks to a $10.5 million award from the National Institute of Mental Health.

1 Oct 2009

Study links stress and stroke

Many patients urgently admitted to hospital with cerebral infarction state that they were under great stress over a prolonged period prior to suffering their stroke, is shown in a unique patient study conducted in cooperation between the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital, Sweden.

1 Oct 2009

Progressive infantile scoliosis responds well to a series of casts: Study

When parents are told their babies' scoliosis needs treatment, they often try bracing first. If that fails, they need surgery to place metal rods in their backs with spinal fusion later on. These children face the risk of complications from the surgery and their backs and chests may be stiff for life.

1 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

Treatment of gestational diabetes benefits both infant and mother

A National Institutes of Health network study provided the first conclusive evidence that treating pregnant women who have even the mildest form of gestational diabetes can reduce the risk of common birth complications among infants, as well as blood pressure disorders among mothers.

1 Oct 2009

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

1 Oct 2009

Cardiac experts study a new procedure to treat leaky heart valves

Cardiac experts at Rush University Medical Center are studying a new, minimally invasive procedure to treat leaky heart valves. Instead of open heart surgery, patients will undergo a less complex catheter-based procedure to treat mitral regurgitation, a serious heart disorder where blood leaks backwards toward the lungs with each heart beat.

1 Oct 2009

Axiomed Spine Corporation receives Ferchill Partner Award for its medical innovation

At the 6th Annual Cleveland Clinic Innovator Awards dinner, AxioMed Spine Corporation (www.axiomed.com) was awarded the Ferchill Partner Award for the company’s medical innovation and economic impact on the community. The Cleveland Clinic and AxioMed Spine Corporation collaborated on the development of the Freedom® Lumbar Disc for the treatment of degenerative disc disease.

1 Oct 2009

Medical Condition News

People with rare mutations of gene MUTYH at increased risk of bowel cancer

New software to detect multiple sclerosis before brain damage occurs

Orexigen's Empatic Phase 2b results demonstrate weight loss

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Women create nationwide movement to eradicate breast cancer

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Grand Opportunity grant to pursue "whole-genome" sequencing of patients with autism

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Intoxicated trauma patients have higher survial rates than sober patients: Study

NIH awards $10.5 million grant for OCD treatment research

Study links stress and stroke

Progressive infantile scoliosis responds well to a series of casts: Study

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Rush University receives grants to study how epigenomic changes define cognitive decline

Treatment of gestational diabetes benefits both infant and mother

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

Cardiac experts study a new procedure to treat leaky heart valves

Axiomed Spine Corporation receives Ferchill Partner Award for its medical innovation

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News